Search
Now showing items 1-1 of 1
Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab
(Springer, 2019)
Human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC) is an aggressive BC subtype characterized by HER2 overexpression/amplification. Genomic alterations of HER2 and others have been reported to be ...